Drugs / SAGE-718
Drug research

SAGE-718

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)NCT05107128SUPNPhase 2Completed2024-09-04Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseNCT05655520SUPNPhase 3Terminated2025-01-20Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)NCT04476017SUPNPhase 2Completed2022-03-25Actual
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692SUPNPhase 2Completed2024-06-05Actual
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseNCT05358821SUPNPhase 2Completed2024-02-29Actual
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentNCT05318937SUPNPhase 2Completed2024-01-17Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624SUPNPhase 2Completed2021-09-28Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.